Omburtamab radiolabeled therapeutic (Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2025/10/21 15:17:02

Base Information

Drug NameOmburtamab radiolabeled therapeutic (Memorial Sloan-Kettering Cancer Center)

Drug Alias NamehuB-7-H-3Hu8H9

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-CD276Ionising radiation emitters

TargetsCD276 antigen

Therapy Area/IndicationsSolid tumoursOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center

Inactive CompaniesN/A

Active IndicationsSolid tumoursOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A